Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Louis Burt Nabors, MD, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00584883
First received: December 26, 2007
Last updated: May 16, 2012
Last verified: May 2012

December 26, 2007
May 16, 2012
August 2003
July 2008   (final data collection date for primary outcome measure)
All patients enrolled in this study will be statistically characterized for baseline and disease characteristics using descriptive statistics for continuous measures. [ Time Frame: up to 2 years ] [ Designated as safety issue: Yes ]
The primary outcome for the study was safety and to define the MTD (max tolerated dose). Also, survival was to be measured but the study was not powered to statistically have significance for that measure.
All patients enrolled in this study wil be statistically characterized for baseline and disease characteristics using descriptive statistics for continuous measures. [ Time Frame: up to 2 years ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00584883 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme
A Phase I Study of ABT 510 and Concurrent Temozolomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme

To determine the maximum tolerated dose of ABT 510 when administered concurrent with radiation therapy for patients with newly diagnosed glioblastoma multiforme.

  1. To describe the toxicity associated with this regimen in adult patients with newly diagnosed glioblastoma multiforme.
  2. To determine the duration of disease free survival and overall survival associated with this therapy.
  3. Evaluate thrombospondin 1 (TSP-1) and 2 (TSP-2) in tumor vs. corresponding normal tissue using quantitative real time Polymerase Chain Reaction (Q-RT-PCR).
  4. Determine the effect of ABT 510 on tumor permeability and tumor blood volume as measured by non-invasive Magnetic Resonance Imaging (MRI).
Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Brain Tumor
Drug: ABT 510
ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
July 2008
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients must be 19 years of age or older.
  2. Patients must have histologically proven newly diagnosed glioblastoma multiforme.
  3. Patients must have fully recovered from the immediate post-operative period and be maintained on a stable corticosteroid regimen for 5 days prior to entry.
  4. Patients must have a Karnofsky performance status > 60% (i.e. the patient must be able to care for himself/herself with occasional help from others).
  5. Patients must have adequate hematologic, renal and liver function (i.e. Absolute neutrophil count > 1500/mm3, Platelets > 100,000/mm3, creatinine 1.5 mg/dl .
  6. Women of childbearing potential must have a negative pregnancy test.
  7. Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. The effect of the investigational drugs on the developing human fetus is not known, but these drugs are likely to be harmful to the developing fetus or nursing infant. Women of child-bearing potential must agree to use adequate contraception (either surgical sterilization; approved hormonal contraceptives such as birth control pills Depo-Provera, or Lupron Depot; barrier methods such as condom or diaphragm along with spermicide; or an Intrauterine device (IUD)). Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician and study PI immediately.
  8. The patient is able to self-administer or has a caregiver who can reliably administer subcutaneous injections.
  9. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Pregnant or breast feeding.
  2. Prior therapy for the brain tumor (except surgery)
  3. Prior treatment with antineoplastic agents.
  4. Exclude sexually active males and females unwilling to practice contraception during the study.
  5. Serious concurrent infections.
  6. Clinically significant cardiac disease not well controlled with medication (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias ) or myocardial infarction within the last 12 months.
  7. Patients who have had prior cytotoxic chemotherapy prior to radiation therapy.
  8. Patients with other serious uncontrolled co-morbid diseases that the investigator feels may comprise the study findings.
  9. Patients must be able to learn to self -administer or have another person administer subcutaneous(SQ) injections.
  10. Patients who have received any other investigational agents within the 28 days prior to Day 1 of the study.

    -

Both
19 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00584883
UAB 0327, ABT510
Yes
Louis Burt Nabors, MD, University of Alabama at Birmingham
University of Alabama at Birmingham
Not Provided
Principal Investigator: Louis B Nabors, MD University of Alabama at Birmingham
University of Alabama at Birmingham
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP